CDC and FDA Recommendation to Pause Use of Johnson & Johnson COVID-19 Vaccine (Talking Points)
Year Developed: 2021
Resource Type: Publication.Primary Audience: Clinicians Outreach Staff Health Center Staff
Language(s): English
Developed by: Centers for Disease Control and Prevention (See other resources developed by this organization). In collaboration with Food and Drug Administration .
Resource Summary: This resource provides talking points concerning the CDC and FDA's recommendation to pause the use of the Johnson & Johnson/Janssen COVID-19 vaccine after six reported U.S. cases of a rare and severe type of blood clot. The recommendation was made in order to prepare the health care system to recognize and treat patients appropriately.
Resource Details: As of April 12, more than 6.8 million doses of the Johnson & Johnson vaccine have been administered in the U.S. CDC and FDA are reviewing data involving six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the J&J vaccine. In these cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of blood platelets (thrombocytopenia). All six cases occurred among women between the ages of 18 and 48, and symptoms occurred 6 to 13 days after vaccination.
Resource Topic: Clinical Issues, Emerging Issues, Operations
Resource Subtopic: COVID-19, Emergency Management.
Keywords: Immunization.This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,625,000 with 0 percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov.